Introduction: Medical cannabinoids have received significant mainstream media attention in recent times due to an evolving political and clinical landscape. Whilst the efficacy of cannabinoids in the treatment of some childhood epilepsy syndromes is increasingly recognized, medical cannabinoids may also have potential clinical roles in the treatment of older adults. Prescribing restrictions for medical cannabinoids in certain jurisdictions (including the UK) has recently been relaxed. However, few geriatricians have the detailed knowledge or awareness of the potential risks or rewards of utilizing cannabinoids in the older person; even fewer geriatricians have direct experience of using these drugs in their own clinical practice. Older persons are more likely to suffer from medical illness representing potential indications for medical cannabinoids (e.g., pain); equally they may be more vulnerable to any adverse effects.
Aim: This narrative literature review aims to provide a brief introduction for the geriatrician to the potential indications, evidence-base, contra-indications and side effects of medical cannabinoids in older people.
Methods: A search was conducted of CENTRAL, Medline, Embase, CINAHL and psycINFO, Cochrane and Web of Science databases. Reference lists were hand searched. Abstracts and titles were screened, followed by a full text reading of relevant articles.
Results: 35 studies were identified as relevant for this narrative review.
Conclusions: Cannabinoids demonstrate some efficacy in the treatment of pain and chemotherapy-related nausea; limited data suggest potential benefits in the treatment of spasticity and anxiety. Risks of cannabinoids in older patients appear to be moderate, and their frequency comparable to other analgesic drug classes. However, the quality of research is weak, and few older patients have been enrolled in cannabinoid studies. Dedicated research is needed to determine the efficiency and safety of cannabinoids in older patients.
Keywords: CBD; THC; cannabinoids; effectiveness; elderly; literature review; safety.
Conflict of interest statement
The authors declare no conflict of interest.
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.Cochrane Database Syst Rev. 2015 Nov 12;2015(11):CD009464. doi: 10.1002/14651858.CD009464.pub2. Cochrane Database Syst Rev. 2015. PMID: 26561338 Free PMC article. Review.
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28. Lancet Psychiatry. 2019. PMID: 31672337
Efficacy and safety of medical cannabinoids in older subjects: a systematic review.Ageing Res Rev. 2014 Mar;14:56-64. doi: 10.1016/j.arr.2014.01.007. Epub 2014 Feb 5. Ageing Res Rev. 2014. PMID: 24509411 Review.
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. Agency for Healthcare Research and Quality (US). 2020. PMID: 32129963 Free Books & Documents. Review.
Palliative Treatment of Cancer-Related Pain [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 09-2005. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH). 2005. PMID: 29320015 Free Books & Documents. Review.
- Department of Health . An Introduction to the Biochemistry & Pharmacology of Medical Cannabis. District of Columbia, Government of District of Columbia Department of Health; Washington, DC, USA: 2019. [(accessed on 6 June 2019)]. Available online: https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Medical%20Cannabis%20An%20Introduction%20to%20the%20Biochemistry%20and%20Pharmacology.pdf.
- Burstein S. Cannabidiol (CBD) and its analogues: A review of their effects on inflammation. [(accessed on 9 May 2019)];Bioorg. Med. Chem. 2015 23:1377–1385. doi: 10.1016/j.bmc.2015.01.059. Available online: https://www.researchgate.net/publication/272373349_Cannabidiol_CBD_and_its_analogs_A_review_of_their_effects_on_inflammation. - DOI - PubMed
- Hillig K., Mahlberg P. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae) [(accessed on 6 June 2019)];Am. J. Bot. 2004 91:966–975. doi: 10.3732/ajb.91.6.966. Available online: https://bsapubs.onlinelibrary.wiley.com/doi/full/10.3732/ajb.91.6.966. - DOI - DOI - PubMed
- Rom S., Persidsky Y. Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation. [(accessed on 6 May 2019)];J. Neuroimmune Pharmacol. 2013 8:608–620. doi: 10.1007/s11481-013-9445-9. Available online: https://link.springer.com/article/10.1007%2Fs11481-013-9445-9. - DOI - PMC - PubMed
- Van der Stelt M., Di Marzo V. Cannabinoid Receptors and Their Role in Neuroprotection. [(accessed on 4 May 2019)];Neuromol. Med. 2005 7:37–50. doi: 10.1385/NMM:7:1-2:037. Available online: https://link.springer.com/article/10.1385%2FNMM%3A7%3A1-2%3A037. - DOI - PubMed